Status:

COMPLETED

Absorption of Drugs Post-Bariatric Surgery (Absorb-Azithromycin)

Lead Sponsor:

University of Alberta

Conditions:

Bariatric Surgery

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

Bariatric (obesity) surgery has become the preferred treatment option for patients with severe obesity and is increasing in popularity. It is commonly performed, with nearly 350 000 operations in the ...

Detailed Description

In the past decade, bariatric surgery has emerged as the preferred treatment option for patients with either severe obesity \[body mass index (BMI) ≥ 40 kg/m2\] or moderate obesity (BMI 35.0-39.9 kg/m...

Eligibility Criteria

Inclusion

  • Male and Female
  • 18 - 60 years old
  • ≥ 3 months post-RYGB surgery or a suitable control for bariatric surgery
  • Able to provide written informed consent.

Exclusion

  • Undergone or undergoing reversal of a previous bariatric procedure which involves further resection or bypass of the intestine.
  • Any major post-operative gastrointestinal complications, such as an anastomotic leak, outlet obstruction or persistent vomiting
  • Currently on azithromycin therapy
  • Any contraindications to azithromycin therapy such as:
  • Allergy or hypersensitivity to the drug
  • liver failure or baseline liver enzymes higher than 3-fold above the upper limit of normal
  • end-stage renal failure (glomerular filtration rate \< 10 ml/min)
  • macrolide hypersensitivity
  • history of torsade de pointes or baseline QTc interval ≥ 500 ms
  • acute illness
  • Pregnant or nursing
  • Concomitant treatment with septra, anti-HIV drugs, digoxin, disopyramide, ergotamine, dihydroergotamine, triazolam, antihistamines (terfenadine, astemizole) and theophylline is also a contraindication to enrolment because of the potential for drug interactions that would affect the blood concentrations of azithromycin or these agents.
  • Any other medical, social or geographic condition, which, in the opinion of the investigator would not allow safe completion of the study protocol.

Key Trial Info

Start Date :

June 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2011

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT01154569

Start Date

June 1 2010

End Date

July 1 2011

Last Update

July 29 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Alberta Hospital

Edmonton, Alberta, Canada, T6G2B7